Deutsche Bank lowered the firm’s price target on Zealand Pharma (ZLDPF) to DKK 750 from DKK 815 and keeps a Hold rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZLDPF:
- Ironwood jumps after FDA rejects Zealand short bowel syndrome drug application
- Zealand Pharma says FDA issues CRL for glepaglutide NDA
- Zealand Pharma announces first participant enrolled in ZUPREME-1
- Zealand Pharma upgraded to Hold from Sell at Danske Bank
- Zealand Pharma initiated with an Overweight at JPMorgan